The incidence of tumor cell contamination of peripheral blood stem cells: A meta-analysis to evaluate the impact of mobilization regimens and the influence on outcomes in breast cancer patients

Acta Haematologica

Volumn 131, Issue 3, 2014, Pages 133-140

  Choi, Sora ^a   Rajan, Suja S ^b   Trivedi, Meghana V ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Breast cancer; Cytokines, granulocyte colony stimulating factor; Mobilization regimen; Peripheral blood stem cell transplant; Tumor cell contamination

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; STEM CELL FACTOR;

ARTICLE; BREAST CANCER; CARCINOGENESIS; HUMAN; META ANALYSIS; ONCOLOGICAL PARAMETERS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TUMOR CELL; TUMOR CELL CONTAMINATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CLINICAL EVALUATION; COCHRANE LIBRARY; GRAFT DYSFUNCTION; GRAFT RECIPIENT; INCIDENCE; MEDLINE; MONOTHERAPY; NEOPLASM; PATIENT ASSESSMENT; PERIPHERAL BLOOD STEM CELL; STEM CELL MOBILIZATION;

ANTINEOPLASTIC AGENTS; BLOOD COMPONENT REMOVAL; BREAST NEOPLASMS; CYTOKINES; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; NEOPLASTIC CELLS, CIRCULATING; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; RISK FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84886732582     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000353478     Document Type: Article

References (43)

1. DiPersio JF, Ho AD, Hanrahan J, Hsu FJ, Fruehauf S: Relevance and clinical implications of tumor cell mobilization in the autologous transplant setting. Biol Blood Marrow Transplant 2011; 17: 943-955.
2. Shimoni A, Körbling M: Tumor cell contamination in re-infused stem cell autografts: does it have clinical significance? Crit Rev Oncol Hematol 2002; 41: 241-250.
3. Corrias MV, Haupt R, Carlini B, Parodi S, Rivabella L, Garaventa A, Pistoia V, Dallorso S: Peripheral blood stem cell tumor cell contamination and survival of neuroblastoma patients. Clin Cancer Res 2006; 12: 5680-5685.
4. Sharp JG, Kessinger A, Mann S, Crouse DA, Armitage JO, Bierman P, Weisenburger DD: Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. J Clin Oncol 1996; 14: 214-219.
5. Syme R, Stewart D, Rodriguez-Galvez M, Luider J, Auer Y, Klassen J, Morris D, Brown C, Russell J, Gluck S: Micrometastases in apheresis products predict shorter progression-free and overall survival in patients with breast cancer undergoing high-dose chemotherapy (HDCT) and autologous blood stem cell transplantation (ABSCT). Bone Marrow Transplant 2003; 32: 307-311.
6. Weaver CH, Moss T, Schwartzberg LS, Zhen B, West J, Rhinehart S, Campos L, Beeker T, Lautersztain L, Messino M, Buckner CD: Highdose chemotherapy in patients with breast cancer: evaluation of infusing peripheral blood stem cells containing occult tumor cells. Bone Marrow Transplant 1998; 21: 1117-1124.
7. Cooper BW, Moss TJ, Ross AA, Ybanez J, Lazarus HM: Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer. J Clin Oncol 1998; 16: 3509-3517.
8. Viret F, Chabannon C, Sainty D, Genre D, Goncalves A, Arnoulet C, Gravis G, Bertucci F, Houvenaeghel G, Jacquemier J, Bardou VJ, Ladaique P, Braud AC, Maraninchi D, Viens P: Occult tumor cell contamination in patients with stage II/III breast cancer receiving sequential high-dose chemotherapy. Bone Marrow Transplant 2003; 32: 1059-1064.
9. Pecora AL, Lazarus HM, Jennis AA, Preti RA, Goldberg SL, Rowley SD, Cantwell S, Cooper BW, Copelan EA, Herzig RH, Meagher R, Kennedy MJ, Akard LR, Jansen J, Ross A, Prilutskaya M, Glassco J, Kahn D, Moss TJ: Breast cancer cell contamination of blood stem cell products in patients with metastatic breast cancer: predictors and clinical relevance. Biol Blood Marrow Transplant 2002; 8: 536-543.
10. Gluck S, Ross AA, Layton TJ, Ostrander AB, Goldstein LC, Porter K, Ho AD: Decrease in tumor cell contamination and progenitor cell yield in leukapheresis products after consecutive cycles of chemotherapy for breast cancer treatment. Biol Blood Marrow Transplant 1997; 3: 316-323.
11. Liu H, Jia D, Fu J, Zhao S, He G, Ling EA, Gao J, Hao A: Effects of granulocyte colony-stimulating factor on the proliferation and cellfate specification of neural stem cells. Neuroscience 2009; 164: 1521-1530.
12. Harada M, Qin Y, Takano H, Minamino T, Zou Y, Toko H, Ohtsuka M, Matsuura K, Sano M, Nishi J, Iwanaga K, Akazawa H, Kunieda T, Zhu W, Hasegawa H, Kunisada K, Nagai T, Nakaya H, Yamauchi-Takihara K, Komuro I: G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat Med 2005; 11: 305-311.
13. Schabitz WR, Kruger C, Pitzer C, Weber D, Laage R, Gassler N, Aronowski J, Mier W, Kirsch F, Dittgen T, Bach A, Sommer C, Schneider A: A neuroprotective function for the hematopoietic protein granulocyte-macrophage colony stimulating factor (GM-CSF). J Cereb Blood Flow Metab 2008; 28: 29-43.
14. Brouard N, Driessen R, Short B, Simmons PJ: G-CSF increases mesenchymal precursor cell numbers in the bone marrow via an indirect mechanism involving osteoclastmediated bone resorption. Stem Cell Res 2010; 5: 65-75.
15. Ohmi C, Matsuyama H, Tei Y, Yoshihiro S, Shimabukuro T, Ohmoto Y, Naito K: Granulocyte colony-stimulating factor may promote proliferation of human bladder cancer cells mediated by basic fibroblast growth factor. Scand J Urol Nephrol 2003; 37: 286-291.
16. Gazitt Y, Shaughnessy P, Liu Q: Differential mobilization of CD34+ cells and lymphoma cells in non-Hodgkin's lymphoma patients mobilized with different growth factors. J Hematother Stem Cell Res 2001; 10: 167-176.
17. Gutschalk CM, Herold-Mende CC, Fusenig NE, Mueller MM: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo. Cancer Res 2006; 66: 8026-8036.
18. Pei XH, Nakanishi Y, Takayama K, Bai F, Hara N: Granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells. Br J Cancer 1999; 79: 40-46.
19. Noda I, Fujieda S, Ohtsubo T, Tsuzuki H, Tanaka N, Sunaga H, Saito H: Granulocytecolony- stimulating factor enhances invasive potential of human head-and-neck-carcinoma cell lines. Int J Cancer 1999; 80: 78-84.
20. Nieto Y, Franklin WA, Jones RB, Berman SI, Pellom J, Baron AE, Shpall EJ: Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous hematopoietic progenitor cell support. Biol Blood Marrow Transplant 2004; 10: 415-425.
21. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339:b2535.
22. Kleinman MB, Wiley EL, Guo M, Rademaker AW, Villa M, Tallman MS, Newman SB, Gordon LI, Winter JN: Immunohistochemical detection of breast cancer cells in paired peripheral blood progenitor cell specimens collected after cytokine or cytokine and myelosuppressive chemotherapy. Bone Marrow Transplant 1999; 23: 1297-1301.
23. Ahn MJ, Noh YH, Lee YS, Lee YY, Choi IY, Kim IS, Joh EK, Shin DB, Kim SY, Cho KS, Kim HC, Kim HS, Suh CW, Kim SH, Lee JA, Park YS: Clinical impacts of tumor cell contamination of hematopoietic stem cell products in metastatic breast cancer patients undergoing autologous peripheral blood stem cell transplantation: multicenter trial. J Korean Med Sci 2001; 16: 175-182.
24. Leone F, Cavalloni G, Gunetti M, Pignochino Y, Piacibello W, Aglietta M: Tumor cell purging by ex vivo expansion of hemopoietic stem cells from breast cancer patients combined with targeting ErbB receptors. Biol Blood Marrow Transplant 2006; 12: 68-74.
25. Franklin WA, Glaspy J, Pflaumer SM, Jones RB, Hami L, Martinez C, Murphy JR, Shpall EJ: Incidence of tumor-cell contamination in leukapheresis products of breast cancer patients mobilized with stem cell factor and granulocyte colony-stimulating factor (G-CSF) or with G-CSF alone. Blood 1999; 94: 340-347.
26. Kroger N, Kruger W, Renges H, Zeller W, Rauhoft C, Loliger C, Zander AR: Comparison of progenitor cell collection on day 4 or day 5 after steady-state stimulation with GCSF alone in breast cancer patients: influence on CD34+ cell yield, subpopulation, and breast cancer cell contamination. J Hematother Stem Cell Res 2000; 9: 111-117.
27. Kruger W, Togel F, Kroger N, Rossing S, Gieseking F, Gutensohn K, Lindner C, Janicke F, Zander AR: Tumour cell detection in G-CSF mobilised stem cell harvests of patients with breast cancer. Med Oncol 1999; 16: 17-22.
28. Stadtmauer EA, Tsai DE, Sickles CJ, Mick R, Luger SM, Porter DL, Mangan PA, Schuchter LM, Schuster SJ, Loh EY, Magee DA, Sachs RA, Wall ME, Moore J, Buzby GP, Zaleta E, Kamoun M, Silberstein LE: Stem cell transplantation for metastatic breast cancer: analysis of tumor contamination. Med Oncol 1999; 16: 279-288.
29. Passos-Coelho JL, Ross AA, Kahn DJ, Moss TJ, Davis JM, Huelskamp AM, Noga SJ, Davidson NE, Kennedy MJ: Similar breast cancer cell contamination of single-day peripheral-blood progenitor-cell collections obtained after priming with hematopoietic growth factor alone or after cyclophosphamide followed by growth factor. J Clin Oncol 1996; 14: 2569-2575.
30. Pecora AL, Lazarus HM, Cooper BW: Breast cancer contamination in peripheral blood stem cell collections association with bone marrow disease and type of mobilization. Blood 1997; 90: 90a.
31. Umiel T, Pecora A, Lazarus H: Breast cancer contamination in peripheral blood stem cell (PBSC) collections associated with bone marrow disease and type of mobilization regimen. Blood 1996; 88: 408a.
32. Pecora A, Lazarus H, Cooper BW: The incidence of breast cancer cell contamination in peripheral blood stem cell (PBSC) collections in relation to the mobilization regimen. Blood 1996; 88: 408a.
33. Pedrazzoli P, Battaglia M, Da Prada GA, Lanza A, Cuomo A, Bertolini F, Pavesi L, Robustelli della Cuna G: Role of tumor cells contaminating the graft in breast cancer recurrence after high-dose chemotherapy. Bone Marrow Transplant 1997; 20: 167-169.
34. Passos-Coelho JL, Ross AA, Moss TJ, Davis JM, Huelskamp AM, Noga SJ, Davidson NE, Kennedy MJ: Absence of breast cancer cells in a single-day peripheral blood progenitor cell collection after priming with cyclophosphamide and granulocyte-macrophage colonystimulating factor. Blood 1995; 85: 1138-1143.
35. Bertolini F, Lanza A, Peccatori F, Zibera C, Gibelli N, Perotti C, Da Prada GA, Torretta L, Cocorocchio E, Martinelli G, Robustelli della Cuna G: Hematopoietic progenitor cell collection and neoplastic cell contamination in breast cancer patients receiving chemotherapy plus granulocyte-colony stimulating factor (G-CSF) or G-CSF alone for mobilization. Ann Oncol 1998; 9: 913-916.
36. Vannucchi AM, Bosi A, Glinz S, Pacini P, Linari S, Saccardi R, Alterini R, Rigacci L, Guidi S, Lombardini L, Longo G, Mariani MP, Rossi- Ferrini P: Evaluation of breast tumour cell contamination in the bone marrow and leukapheresis collections by RT-PCR for cytokeratin-19 mRNA. Br J Haematol 1998; 103: 610-617.
37. Patriarca F, Sacco C, Sperotto A, Geromin A, Damiani D, Fili C, Cerno M, Clochiatti L, Cartei G, Fanin R: Prognostic significance of the detection of tumour cells in peripheral blood stem cell collections in stage II and III breast cancer patients treated with high-dose therapy. Bone Marrow Transplant 2003; 31: 789-794.
38. Ross AA, Layton TJ, Ostrander AB, Passos- Coelho JL, Davis JM, Huelskamp AM, Noga SJ, Davidson NE, Kennedy MJ, Cooper BW, Gerson SL, Lazarus HM, Holland K, Gluck S, Moss TJ, Kaubish A, Vahdat L, Antman K: Comparative analysis of breast cancer contamination in mobilized and nonmobilized hematopoietic grafts. J Hematother 1996; 5: 549-552.
39. Müller AM, Kohrt H, Cha S, Laport G, Klein J, Guardino AE, Johnston LJ, Stockerl-Goldstein KE, Hanania E, Juttner C, Blume KG, Negrin RS, Weissman IL, Shizuru JA: Longterm outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells. Biol Blood Marrow Transplant 2012; 18: 125-133.
40. López-Pérez R, Garcia-Sanz R, González D, Balanzategui A, Chillón MC, Alaejos I, Mateos MV, Caballero MD, Mateo G, Nieto MJ, González M, San Miguel JF: The detection of contaminating clonal cells in apheresis products is related to response and outcome in multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Leukemia 2000; 14: 1493-1499.
41. Brown JR, Feng Y, Gribben JG, Neuberg D, Fisher DC, Mauch P, Nadler LM, Freedman AS: Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant 2007; 13: 1057-1065.
42. Vogel W, Kopp H, Kanz L, Einsele H: Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation. J Cancer Res Clin Oncol 2005; 131: 214-218.
43. Vose JM, Sharp G, Chan WC, Nichols C, Loh K, Inwards D, Rifkin R, Bierman PJ, Lynch JC, Weisenburger DD, Kessinger A, Armitage JO: Autologous transplantation for aggressive non- Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol 2002; 20: 2344-2352.